Dr Cannon graduated from the Royal Free and University College Medical School in 2002 with distinctions in his final medical examinations. He undertook his basic postgraduate medical training in London at St Thomas’ and the Royal Brompton Hospitals before moving to the Eastern Deanery for his higher medical training in Respiratory and General Internal Medicine.
During this training he undertook research into the role of bone morphogenetic signalling in zebrafish vascular development, which led to the award of his PhD from The University of Cambridge. He sub-specialised in pulmonary vascular diseases and was awarded a Masters Degree from The University of Bologna in 2013. He was appointed as a Consultant Respiratory Physician at Royal Papworth Hospital in the Pulmonary Vascular Diseases Unit in 2013.
Pulmonary arterial hypertension
Acute and chronic thromboembolic disease
Chronic thromboembolic pulmonary hypertension
Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
1999 Intercalated BSc (1st class), University of London
2002 MBBS (Distinctions in Medicine, Surgery, Pathology and Clinical Pharmacology and Therapeutics), University of London
2005 MRCP UK (London)
2008 NIHR Cambridge BRC Clinical Training Fellowship
2008 Sackler Fellowship
2012 PhD, University of Cambridge
2012 Masters in Pulmonary Vascular Diseases, University of Bologna
2013 CCT Respiratory and General internal Medicine
Member of British Thoracic Society
Member of the Royal College of Physicians (London)
Member of General Medical Council (registration number: 6054021)
Member of International CTEPH Association
Member of International Society of Heart and Lung
Cannon JE, Su L, Kiely DG, Page K, Toshner M, Swietlik E, Treacy C, Ponnaberanam A, Condliffe R, Sheares K, Taboada D, Dunning J, Tsui S, Ng C, Gopalan D, Screaton N, Elliot C, Gibbs S, Howard L, Corris P, Lordan J, Johnson M, Peacock A, MacKenzie-Ross R, Schreiber B, Coghlan G, Dimopoulos K, Wort SJ, Gaine S, Moledina S, Jenkins DP, Pepke-Zaba J. Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: Results From the United Kingdom National Cohort. Circulation. 2016 May 3;133(18):1761-71. doi: 10.1161/CIRCULATIONAHA.115.019470. Epub 2016 Apr 6.
Cannon JE, Pepke-Zaba J. Response by Cannon and Pepke-Zaba to Letter Regarding Article, "Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: Results From the United Kingdom National Cohort". Circulation. 2016 Oct 4;134(14):e301-e302.
Ali JM, Dunning J, Ng C, Tsui S, Cannon JE, Sheares KK, Taboada D, Toshner M, Screaton N, Pepke-Zaba J, Jenkins DP. The outcome of reoperative pulmonary endarterectomy surgery. Interact Cardiovasc Thorac Surg. 2018 Jun 1;26(6):932-937. doi: 10.1093/icvts/ivx424.
Bostock S, Sheares K, Cannon J, Taboada D, Pepke-Zaba J, Toshner M. The potential effects of pregnancy in a patient with idiopathic pulmonary arterial hypertension responding to calcium channel blockade. Eur Respir J. 2017 Dec 14;50(6). pii: 1701141. doi: 10.1183/13993003.01141-2017. Print 2017 Dec.
Newnham M, Hernández-Sánchez J, Dunning J, Ng C, Tsui S, Bunclark K, Sheares K, Taboada D, Toshner M, Pepke-Zaba J, Jenkins D, Cannon J. Age should not be a barrier for pulmonary endarterectomy in carefully selected patients. Eur Respir J. 2017 Dec 7;50(6). pii: 1701804. doi: 10.1183/13993003.01804-2017. Print 2017 Dec.
Cannon JE, Pepke-Zaba J. Contemporary diagnosis and management of pulmonary hypertension. Heart. 2016 Oct 15;102(20):1680-91. doi: 10.1136/heartjnl-2015-307996.
Taboada D, Pepke-Zaba J, Jenkins DP, Berman M, Treacy CM, Cannon JE, Toshner M, Dunning JJ, Ng C, Tsui SS, Sheares KK. Outcome of pulmonary endarterectomy in symptomatic chronic thromboembolic disease.
Eur Respir J. 2014 Dec;44(6):1635-45. doi: 10.1183/09031936.00050114. Epub 2014 Sep 18.
Cannon JE, Pepke-Zaba J. Riociguat for pulmonary hypertension. Expert Rev Clin Pharmacol. 2014 May;7(3):259-70. doi: 10.1586/17512433.2014.893818. Epub 2014 Mar 3.
Cannon JE, Pepke-Zaba J. Is distal chronic thromboembolic pulmonary hypertension treatable with PAH targeted drugs?
Semin Respir Crit Care Med. 2013 Oct;34(5):620-6. doi: 10.1055/s-0033-1355442. Epub 2013 Sep 13.
SwitchBoard: 01480 830541
Fax: 01480 834267
Tel: 01223 639697